Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225382 | 0.88 | MEN1 (0.39) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL25272726 | 0.77 | PDE4B (0.41) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22004731 | 0.77 | EPHX2 (0.40) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL1224512 | 0.74 | USP2 (0.45) | NR1H2EPHX2USP2SMN1; SMN2EPHX1 | |
| SCHEMBL2604310 | 0.73 | PKM (0.46) | EPHX2USP2SMN1; SMN2EPHX1PKM | |
| SCHEMBL3654641 | 0.72 | NR1H2 (0.37) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL17763768 | 0.72 | USP2 (0.40) | NR1H2EPHX2USP2SMN1; SMN2 | |
| SCHEMBL31511515 | 0.72 | USP2 (0.45) | NR1H2ALDH1A1MAPTEPHX2USP2 | |
| SCHEMBL3493196 | 0.71 | USP2 (0.39) | ALDH1A1EPHX2USP2SMN1; SMN2EPHX1 | |
| SCHEMBL2473165 | 0.71 | PKM (0.42) | EPHX2USP2SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841562-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | AVENTIS PHARMA S.A. (FR) | 2005-01-11 | — | — | US | disclosed |
| US-6815547-B2 | ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS | AVENTIS PHARMA S.A. (FR) | 2004-11-09 | — | — | US | disclosed |
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL (FR) | 2004-04-29 | — | — | US | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | NR1H2 2368/4885ALDH1A1 1808/4885MEN1 2329/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | NR1H2 2368/4885ALDH1A1 1808/4885MEN1 2329/4885 |
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | RRS1, MRPL21, FARSB | NR1H2 152/4885ALDH1A1 1452/4885MEN1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.